SPOTLIGHT: CytRx reviews toxicology data

Last week the FDA halted CytRx Phase II trial of a drug for Lou Gehrig's disease in order to analyze results from animal studies of arimoclomol. The FDA has clarified its decision and CytRx is now analyzing data from the previously completed toxicology study to prepare a response to the issues cited by the FDA. Release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.